Ik vind hier niet direct het artikel van juli 2020waarin de superioriteit t.o.v. ALLE concurrentie van bimekizu vermeld wordt:
UCB shareholders unmoved by psoriasis hit
Trumpeting its psoriasis candidate bimekizumab’s superiority in the Be Radiant head-to-head trial against Novartis’s Cosentyx today has gained UCB little: with no data released there is no way to gauge exactly how well the IL-17A and IL-17F inhibitor stacks up against the variety of MAbs already occupying this space. That said, efficacy data from the placebo-controlled Be Ready trial, released in June, were pretty spectacular, so if the Be Radiant results come in at a similar level bimekizumb could shake up the market. The primary endpoint of te Be Radiant study, Pasi 100 response at four months, differs from the claims other psoriasis MAbs make on their labels, meaning that comparisons against anything other than Cosentyx will rely on secondary endpoints, including 48-week data, once UCB releases the actual figures. Given the impressive Be Ready data, sellside consensus sales forecasts for bimekizumab, as calculated by EvaluatePharma, seem rather low at $931m in 2026.
Ik slaag er niet in de tabel te copiëren maar het staat in Evaluate Vantage van 24 juli 2020